dr. hill on the fda approval of selinexor in dlbcl
Published 4 years ago • 104 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
1:15
dr. hill on the sadal trial with selinexor in dlbcl
-
1:38
dr. hill on the safety profile of selinexor in relapsed/refractory dlbcl
-
1:16
dr. richardson discusses the fda approval of selinexor in myeloma
-
0:36
copy of dr. richardson discusses the fda approval of selinexor in myeloma
-
1:11
the role of selinexor in dlbcl and the challenges of implementing this agent in patients
-
1:54
dr. jagannath on the safety profile of selinexor in multiple myeloma
-
2:23
dr. jeremy larson on selinexor (xpovio)
-
1:16
dr. leonard on the fda approval of tazemetostat in follicular lymphoma
-
1:06
dr. stadtmauer on selinexor update
-
4:08
what is the latest on a new drug called selinexor?
-
2:00
the sadal study: selinexor for r/r dlbcl
-
1:03
dr. dimopoulos on evolution of selinexor in multiple myeloma
-
9:25
fda approvals in large b-cell lymphoma and melanoma, priority reviews in cscc and nsclc, and more
-
6:42
sadal trial regimen fda approval
-
0:57
dr. andreadis on the treatment of relapsed dlbcl
-
1:07
dr. waxman on selinexor in multiple myeloma treatment
-
2:02
update on selinexor for myeloma and large cell lymphomas
-
1:15
dr. welslau on the benefits of biosimilars in dlbcl
-
4:29
considering selinexor in penta-refractory myeloma